On June 26, the three-day 23rd CPHI China and the 18th PMEC China were successfully concluded at the Shanghai New International Expo Center. At this annual event of the pharmaceutical industry, Bangkai Materials used technology as a sail and innovation as a paddle to explore new paths for technological collaboration in the integration and communication of upstream and downstream of the industrial chain.

With 17 years of experience in the field of silica, Bangkai Materials has always focused on the research and development, production and service of "microporous silica" inorganic materials. It is a specialized and innovative enterprise that breaks through technical barriers with hard technology. Our core product, gel-based silica, accurately serves diversified application scenarios such as analysis and testing, separation and purification, food industry, scientific research analysis, and intelligent display.

At this CPHI, relying on the exhibition platform, Bangkai conducted in-depth discussions with many customers on core topics such as the pain points of the actual application of silica, and responded promptly to customer feedback and output customized solutions. Many new and old customers highly recognized the quality and professional services of Bangkai's silica products in the exchange of applications and technologies, and reached a number of cooperation intentions.

Solve pain points and create value:

★ Feedback from partner companies confirms that Bangkai silica can significantly improve API separation accuracy, increase sample loading and extend the service life of chromatographic columns in downstream applications with its uniform particle size distribution, high mechanical strength and controllable microporous structure.

★ Significant advantages of pharmaceutical excipient-grade products: Bangkai pharmaceutical excipient-grade silica products strictly follow regulatory requirements and provide reliable moisture-proof, anti-static, sustained-release, dispersion, flow-aid and other full-range functional guarantees for solid preparations through customized services.

Based on technology, driving industry collaboration:

As a company focusing on the research and development and production of silicon dioxide, Bangkai keeps a close eye on market demand and continues to carry out technical research. We have not only achieved breakthroughs in many core technologies, but also committed to building a value closed loop of "technology research and development-product implementation-industry collaboration".

 Assisting industry upgrades and consolidating supply chain security:

At present, the global pharmaceutical industry landscape is accelerating its reconstruction. Bangkai's gel-based silica products accurately match international quality, directly hit the key bottlenecks in the production of raw materials, and effectively help downstream companies improve production efficiency and product quality. By providing high-performance domestic alternatives, Bangkai actively helps customers reduce their dependence on imports of key materials, consolidates the cornerstone of supply chain security, and uses the certainty of its own high-quality development to help partners cope with the uncertainty of the external environment and jointly promote the upgrading of the domestic pharmaceutical industry.